Inscobee

Inscobee is a South Korean conglomerate that has strategically pivoted into the life sciences and biotechnology sectors. The company is primarily recognized for its research into bee venom-derived peptides, specifically apamin, which it utilizes for both pharmaceutical development and high-end functional cosmetics under the brand Lapizta. Through its majority-owned subsidiary, OncoPep, Inscobee is developing a pipeline of targeted cancer immunotherapies, including the lead cancer vaccine candidate PVX-410. This candidate is currently in Phase 2 clinical trials for indications such as multiple myeloma and triple-negative breast cancer. Beyond its biotech operations, Inscobee maintains diverse business units in telecommunications and smart grid technology, which provide a stable financial foundation for its clinical pursuits.